We are a preclinical-stage therapeutics company leveraging human-identical molecules as new medicines to treat large patient populations underserved by current treatment options. Our initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells as well as the gut microbiome.
We believe our synthetic biology-manufactured human-identical milk oligosaccharide, or HiMO, drug candidates have the potential to affect multiple pathways implicated in gut-brain axis disorders and certain inflammatory disorders, while reproducing the favorable safety and tolerability profile observed of HMOs. We are prioritizing the development of our drug candidates for disorders where available treatment options are inadequately serving patients due to safety or tolerability issues and where we have the potential to redefine the standard of care.
We believe our synthetic biology-manufactured human-identical milk oligosaccharide, or HiMO, drug candidates have the potential to affect multiple pathways implicated in gut-brain axis disorders and certain inflammatory disorders, while reproducing the favorable safety and tolerability profile observed of HMOs. We are prioritizing the development of our drug candidates for disorders where available treatment options are inadequately serving patients due to safety or tolerability issues and where we have the potential to redefine the standard of care.
Location: United States, Washington, Seattle
Employees: 1-10
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | WRF Capita... | wrfseattle... |
Mentions in press and media 4
| Date | Title | Description |
| 08.12.2022 | Tech Moves: Ex-RealSelf leader joins Oggvo; ex-Adaptive CFO lands at Capella Space; and more | Maureen Ezekwugo. (Oggvo Photo) — Maureen Ezekwugo is now CEO of Oggvo, which develops customer review management software for small- to medium-sized businesses. Ezekwugo was previously at Seattle-based cosmetic treatment review platform Re... |
| 07.12.2022 | SPAC deal folds for Seattle biotech startup, months after IPO withdrawal | Intrinsic Medicine CEO Alex Martinez. (Intrinsic Photo) A deal to take Seattle biotech company Intrinsic Medicine public via a SPAC merger has fallen apart. The SPAC deal, announced in October, would have taken the startup public via a merg... |
| 31.10.2022 | Seattle startup developing therapies based on human milk to go public via SPAC merger | Intrinsic Medicine CEO Alex Martinez. (Intrinsic Medicine Photo) Seattle startup Intrinsic Medicine plans to go public through a merger with a shell company, Phoenix Biotech Acquisition Corp. The four-year old biotech startup is developing ... |
| 07.09.2022 | Arpeggio Biosciences rakes in $17M to measure the transcriptome | How can drug developers design therapies around cellular networks rather than a single target? That is the question Arpeggio Biosciences is seeking to answer — and with a new influx of funds. The Boulder, Colorado-based startup announced th... |